Abstract:Key PointsMHC class II molecules bind antigenic peptides that are generated in endosomal–lysosomal antigen-processing compartments. These peptides are derived from proteins that access these compartments using various endocytic pathways and also as a result of autophagy.Proteolysis in antigen-processing compartments is regulated in antigen-presenting cells (APCs) to favour the formation of antigenic peptides that can bind to MHC class II and to avoid the complete hydrolysis of proteins to very short peptides or to amino acids.Nonspecific endocytosis processes are terminated following dendritic cell (DC) activation, but mature DCs can still internalize antigen by receptor-mediated endocytosis or phagocytosis. Using these pathways, mature DCs can generate peptide–MHC class II complexes and activate naive CD4+ T cells.The formation of antigen-processing compartments is regulated during APC activation. B cell activation results in MHC class II recruitment to endosomes and lysosomes to form these compartments, whereas in DCs, lysosomal proteases relocalize to antigen-processing compartments and enhance antigen proteolysis.APC activation leads to efficient generation of peptide–MHC class II complexes and markedly increases the expression of these complexes on the APC plasma membrane. Increased surface expression of peptide–MHC class II complexes on activated APCs is a result of enhanced MHC class II transcription and/or translation, movement of intracellular peptide–MHC class II complexes to the APC plasma membrane and reduced lysosomal MHC class II degradation.Expression of the E3 ubiquitin ligase MARCH1 by immature APCs promotes rapid turnover of peptide–MHC class II complexes. DC activation terminates MARCH1 expression and ubiquitylation of peptide–MHC class II complexes, thus increasing the half-life of peptide–MHC class II complexes.

The Introduction on the Principle of Directional Antigen Presentation System Based on MHC-Ⅱ Restriction

Mechano-regulation of Peptide-MHC Class I Conformations Determines TCR Antigen Recognition.

Identification of Human T Cell Receptor Γδ-Recognized Epitopes/Proteins Via CDR3δ Peptide-based Immunobiochemical Strategy

A general platform for targeting MHC-II antigens via a single loop

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

MHC class II restricted neoantigen: A promising target in tumor immunotherapy

Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation

The Involvement of Antigen Processing in Determinant Selection by Class II MHC and Its Relationship to Immunodominance

Expression of MHC II genes

Mechanism study of cross presentation of exogenous antigen induced by cholera toxin-like chimeric protein

Endogenous Antigen Presentation of MHC Class II Epitopes through Non-Autophagic Pathways

Plasma Membrane Interactions That Determine Presentation of Antigens by Antigen-presenting Cells. (P5022)

Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation

MHC Class II Restricted Neoepitope Vaccine: Promising Strategy for Immunotherapy.

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy

Targeting MHC-I Molecules for Cancer: Function, Mechanism, and Therapeutic Prospects

Molecular Characteristics, Functional Definitions, and Regulatory Mechanisms for Cross-Presentation Mediated by the Major Histocompatibility Complex: A Comprehensive Review

The ins and outs of MHC class II-mediated antigen processing and presentation

Herpesviruses Placating the Unwilling Host: Manipulation of the MHC Class II Antigen Presentation Pathway

Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects.

Delivery of nanoparticle antigens to antigen-presenting cells: from extracellular specific targeting to intracellular responsive presentation